Britain's competition watchdog probes Iberdrola merger with NWEN-March 2024-www.financetom.com

Britain's competition watchdog probes Iberdrola merger with NWEN

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Britain's competition watchdog probes Iberdrola merger with NWEN

Jan 28, 2025 11:48 PM

LONDON, Jan 29 (Reuters) - Britain's Competition and

Markets Authority said on Wednesday it was weighing whether a

merger of Spain's Iberdrola and NWEN Ltd could reduce

competition in the energy sector, and make it tougher for market

regulators to keep track of pricing.

The CMA has set a deadline of March 27 for submissions by

interested parties to phase 1 of its merger enquiry.

Previous page： Google agrees $36 million fine for anti-competitive deals with Australia telcos Next page： Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

Apr 8, 2025

08:59 AM EDT, 04/08/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said Tuesday the first patient has been dosed in a phase 1 clinical study of REC-3565 for the potential treatment of relapsed or refractory B-cell lymphomas. The investigational drug has demonstrated evidence of durable tumor regression in preclinical trials as a monotherapy and in combination with a BTK...

South Korea's acting president talks with Trump ahead of 25% tariff

Apr 8, 2025

By Ju-min Park and Jihoon Lee SEOUL (Reuters) -South Korea's acting President Han Duck-soo on Tuesday spoke with President Donald Trump over the phone, a day before Trump's 25% tariff on the Asian ally is scheduled to kick in. It is the first time Trump spoke with any of South Korea's acting leaders since he took office in January, while...

NextDecade signs 20-year deal with Aramco to supply LNG from Rio Grande facility

Apr 8, 2025

April 8 (Reuters) - U.S. liquefied natural gas producer NextDecade ( NEXT ) said on Tuesday it had signed an agreement with a subsidiary of Saudi Aramco to supply the superchilled gas from its Rio Grande facility for 20 years. As part of the deal, the Aramco subsidiary will purchase 1.2 million tonnes per annum of LNG from Train 4...